Wednesday delivered a solid session for U.S. equities, with the Dow Jones index climbing around 200 points as investors cheered a flurry of corporate developments and FDA approvals that sent several healthcare stocks into the stratosphere.

The Headline Maker: Sanofi Scoops Up Dynavax

The day's biggest story came from the biotech world, where Dynavax Technologies Corp (DVAX) became the latest acquisition target. Sanofi SA (SNY) agreed to buy the company for $15.50 per share in an all-cash transaction that values Dynavax's equity at approximately $2.2 billion.

For Sanofi, the deal represents a strategic expansion of its adult immunization business. For Dynavax shareholders, it represented an immediate windfall as shares rocketed 38.6% to $15.44 on Wednesday.

FDA Approval Season Delivers Big Winners

If you're keeping score on FDA approvals, Wednesday was a banner day. Omeros Corp (OMER) absolutely exploded higher, jumping 66.8% to $14.60 after the FDA gave the green light to YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. That's a mouthful of medical terminology, but for investors, it translated into a stock that nearly doubled in a single session.

Not far behind was Agios Pharmaceuticals Inc (AGIO), which surged 17.9% to $29.00 following FDA approval of AQVESME for treating anemia in adults with alpha- or beta-thalassemia. An executive announced that AQVESME will be introduced at approximately $425,000 per patient per year, putting it squarely in the ultra-premium drug category.

Clinical Data Moves Markets Too

You don't always need final FDA approval to move a stock. Edgewise Therapeutics Inc (EWTX) gained 23.8% to $26.94 after the company shared updates from its ongoing CIRRUS-HCM Phase 2 trial of EDG-7500. Positive clinical trial data can be just as exciting as approvals, especially when the market likes what it sees.

Similarly, Immuneering Corp (IMRX) rose 6.8% to $6.83 after announcing it would provide an update on 12-month overall survival data from its ongoing Phase 2a clinical trial of atebimetinib plus mGnP in first-line pancreatic cancer patients on January 7, 2026. Sometimes just knowing when you'll get important data is enough to spark investor interest.

Other Notable Gainers Across Sectors

Beyond biotech, several other stocks posted impressive gains. UiPath Inc (PATH) jumped 7.9% to $17.23 after the announcement that it will replace Synovus Financial in the S&P MidCap 400. Index inclusion might sound boring, but it often means forced buying from index funds, which investors tend to like.

Polestar Automotive Holding Uk Plc (PSNY) jumped 11.8% to $16.92 following the recent announcement of a $300 million equity investment from Banco Bilbao Vizcaya Argentaria and Natixis. Fresh capital is always welcome, especially in the cash-hungry EV sector.

Falcon's Beyond Global Inc (FBYD) jumped 9.4% to $18.35 after recently announcing the filing of a $100 million mixed shelf offering, giving the company additional financing flexibility.

Nike Balances Insider Confidence Against Headwinds

Nike Inc (NKE) gained 4.7% to $60.03 as investors weighed a notable insider purchase against ongoing concerns around tariffs, China demand, and a slower-than-expected turnaround. Insider buying often signals confidence, but Nike's challenges haven't disappeared overnight.

The Rest of the Winners

Rounding out Wednesday's gainers were several other stocks posting solid advances. Travere Therapeutics Inc (TVTX) gained 14.3% to $40.41, while Wheels Up Experience Inc (UP) gained 14.8% to $0.73. Coincheck Group NV (CNCK) surged 12.5% to $2.88, and CapsoVision Inc (CV) gained 11.6% to $14.39.

In the biotech space, X4 Pharmaceuticals Inc (XFOR) gained 9.5% to $4.52, BIOAGE Labs Inc (BIOA) jumped 8.8% to $14.37, and Kodiak Sciences Inc (KOD) gained 8.6% to $29.81.

Even the chip sector participated, with Micron Technology Inc (MU) gaining 3.5% to $286.01 as semiconductor stocks continued their recent momentum.

Wednesday proved that when good news hits, especially in the biotech sector, the gains can be dramatic. Between major acquisitions, FDA approvals, and promising clinical data, there was plenty for growth investors to celebrate.